Back to homepage

Tag "immunotherapy"

Agents to treat BRAF-mutant lung cancer

Authors: Jean G Bustamante Alvarez MD, MS, Gregory A Otterson MD

Keywords: dabrafenib, immunotherapy, lung neoplasm, protooncogene protein B-raf, trametinib. Citation: Bustamante Alvarez JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs in Context 2019; 8: 212566. DOI: 10.7573/dic.212566 Contributions: Both authors contributed equally to the preparation of this review.

More

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Authors: Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

More

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Authors: Nicola Personeni MD, Tiziana Pressiani MD, Armando Santoro MD, Lorenza Rimassa MD

Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).

More

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

Authors: Matteo Santoni MD, Francesco Massari MD, Vincenzo Di Nunno MD, Alessandro Conti MD, Alessia Cimadamore MD, Marina Scarpelli MD, Rodolfo Montironi PhD, Liang Cheng PhD, Nicola Battelli MD, Antonio Lopez-Beltran PhD

This editorial describes the results of the most recent clinical trials on the use of immunotherapies in renal cell carcinoma and research for reliable biomarkers of tumour response in this setting, as well as the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies.

More

Harnessing the immune system in the battle against breast cancer

Authors: Elizabeth S Nakasone MD, PhD, Sara A Hurvitz MD, Kelly E McCann MD, PhD

This article examines the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.

More